Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial | | 2022 |
Advanced age portends poorer prognosis after radical prostatectomy: a single center experience | | |
Factors influencing survival in metastatic castration resistant prostate cancer therapy | | |
Stereotactic radiotherapy of nodal oligometastases from prostate cancer: a prisma-compliant systematic review | | |
Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment | | |
Immediate Versus Salvage Postoperative Radiotherapy in High-Risk Prostate Cancer Patients: A Critical Review | | 2022 |
Safety and Efficacy of Carbon-Ion Radiotherapy for Elderly Patients with High-Risk Prostate Cancer | | 2022 |
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer | | |
Assessment of Second Primary Cancer Risk Among Men Receiving Primary Radiotherapy vs Surgery for the Treatment of Prostate Cancer | | 2022 |
Systemic Treatments and Related Side Effects in Prostate Cancer | | 2022 |
Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer | Scientific Reports | 2022 |
The Impact of Gleason Grade 3 as a Predictive Factor for Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group) | Medicina (Lithuania) | 2022 |
Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collaborative | Urologic Oncology: Seminars and Original Investigations | 2022 |
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer | Prostate Cancer and Prostatic Diseases | |
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial | Acta Oncológica | |
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends | Clinical Drug Investigation | |
Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer | Cancers | 2022 |
Prostate specif c antigen density as a prognostic factor in patients with prostate cancer treated with combined hormonal radiation therapy | Siberian Journal of Oncology | 2022 |
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration‐resistant prostate cancer | Prostate | |
More Unacceptable Denials: Now It’s PSMA-Targeted PET/CT Imaging | Journal of Nuclear Medicine | 2022 |
PET-CT in Clinical Adult Oncology—IV. Gynecologic and Genitourinary Malignancies | Cancers | 2022 |
The Latest Data Specifically Focused on Long-Term Oncologic Prognostication for Very Old Adults with Acute Vulnerable Localized Prostate Cancer: A Nationwide Cohort Study | Journal of Clinical Medicine | 2022 |
Comparison of Estimated Late Toxicities between IMPT and IMRT Based on Multivariable NTCP Models for High-Risk Prostate Cancers Treated with Pelvic Nodal Radiation | International Journal of Particle Therapy | 2022 |
Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset | Urologic Oncology: Seminars and Original Investigations | 2022 |
A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report | BMC Medical Genomics | 2022 |
Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10 | Cancers | 2022 |
Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management | European Journal of Nuclear Medicine and Molecular Imaging | |
Clinical implications of homologous recombination repair mutations in prostate cancer | Prostate | 2022 |
Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy | Brachytherapy | 2022 |
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer | Expert Review of Anticancer Therapy | |
Race‐specific prostate cancer outcomes in a cohort of low and favorable‐intermediate risk patients who underwent external beam radiation therapy from 1990 to 2017 | Cancer Medicine | |
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. | Current Oncology Reports | 2022 |
Recent results of HDR brachytherapy in the treatment of localized forms of prostate cancer | Ukrainian Journal of Radiology and Oncology | 2022 |
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval. | Molecular Diagnosis and Therapy | 2022 |
Evolving trends in the management of low-risk prostate cancer | Clinical Genitourinary Cancer | 2022 |
Long-Term Medical Resource Consumption of Radical Prostatectomy vs. Intensity-Modulated Radiotherapy for Old Patients With Prostate Cancer: A Nationwide Population-Based Cohort Study. | Frontiers in Medicine | 2022 |
Quality of life after definitive linear accelerator-based stereotactic radiotherapy for prostate cancer: a longitudinal study. | Radiation Oncology | 2022 |
Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer. | BMC Cancer | 2022 |
Assessment of toxicity of elective pelvic lymph node irradiation in patients with high-risk prostate cancer | Onkologiya Zhurnal Imeni P A Gertsena | 2022 |
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. | Journal of Medical Economics | 2022 |
Table_1.docx | | 2020 |
Data_Sheet_1.ZIP | | 2020 |
DataSheet_1.docx | | 2020 |
Table_1.DOCX | | 2020 |
"Meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer" (MENHYP-ENI). | International Journal of Radiation Oncology Biology Physics | 2022 |
Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomy | Prostate | 2021 |
Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study. | Prostate Cancer and Prostatic Diseases | 2021 |
Prostate Cancer Treatment with Pencil Beam Proton Therapy Using Rectal Spacers sans Endorectal Balloons | International Journal of Particle Therapy | 2022 |
Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers. | Research and Reports in Urology | 2022 |
Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image-Guided Intensity-Modulated Radiotherapy for Localized High-Risk Prostate Adenocarcinoma | Advances in Radiation Oncology | 2022 |
Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate Cancer. | Frontiers in Oncology | 2022 |
Prediction of surgical margin status and location after radical prostatectomy using positive biopsy sites on 12-core standard prostate biopsy. | Scientific Reports | 2022 |
Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy. | Radiologia Medica | 2022 |
Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents. | Advances in Therapy | 2022 |
Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker. | Cancers | 2022 |
Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer. | European Radiology | 2022 |
Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel. | Frontiers in Oncology | 2022 |
Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada. | Prostate Cancer and Prostatic Diseases | 2022 |
Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables. | Journal of Racial and Ethnic Health Disparities | 2022 |
Urban-rural prostate cancer disparities in a regional state of Australia. | Scientific Reports | 2022 |
Germline alterations among Hispanic men with prostate cancer. | Prostate Cancer and Prostatic Diseases | 2022 |
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy. | Journal of Personalized Medicine | 2021 |
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. | JAMA Network Open | 2021 |
Prognostic significance of PTEN, RB1 and BRCA2 gene loss in patients with localized and locally advanced prostate cancer | Onkourologiya | 2022 |
Nomograms for Metastasis-Free and Overall Survival for Pathologically Node Positive Prostate Cancer Patients Treated With or Without Radiation Therapy Plus Short-Term ADT. | Clinical Genitourinary Cancer | 2022 |
Combinatorial radiation therapy for prostate cancer with seminal vesicle invasion | Onkourologiya | 2022 |
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. | European Urology | 2021 |
Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer. | Brachytherapy | 2022 |
Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis. | Frontiers in Pharmacology | 2021 |
Prostate Health Index () and its derivatives predict Gleason score upgrading after radical prostatectomy among patients with low-risk prostate cancer | Asian Journal of Andrology | 2021 |
Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective Study. | Frontiers in Oncology | 2021 |
Approach to the Treatment of Metastatic Castration-Sensitive Prostate Carcinoma: A Single Center Experience | Journal of Basic and Clinical Health Sciences | |
Genitourinary System Cancers | | 2022 |
Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD. | Prostate Cancer and Prostatic Diseases | 2022 |
Prognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer. | Journal of Personalized Medicine | 2022 |
Practice-level variation in the decision to biopsy PI-RADS 3 lesions in favorable-risk prostate cancer patients. | Urology | 2022 |
PROFOUND trial -a new era in targeted therapeutics for prostate carcinoma. | Indian Journal of Urology | 2022 |
Testosterone levels and testosterone kinetics: The importance of its clinical significance. | Radiotherapy and Oncology | 2022 |
Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. | Journal of Personalized Medicine | 2022 |
Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview. | World Journal of Men?s Health | 2022 |
Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer. | Clinical Genitourinary Cancer | 2021 |
Osteoporosis: Common Side Effect | Clinical Journal of Oncology Nursing | 2021 |
Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity | Journal of Personalized Medicine | 2021 |
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models) | International Journal of Molecular Sciences | 2021 |
Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial | Supportive Care in Cancer | 2021 |
Application of Machine Learning Techniques to Predict Bone Metastasis in Patients with Prostate Cancer | Cancer Management and Research | 2021 |
Biomarkers for Treatment Response in Advanced Prostate Cancer | Cancers | 2021 |
Comparison of Clinical Outcomes of Radical Prostatectomy versus IMRT with Long-Term Hormone Therapy for Relatively Young Patients with High- to Very High-Risk Localized Prostate Cancer | Cancers | 2021 |
The Impact of 18F-DCFPyL PSMA PET-CT in the Management of Prostate Cancer Biochemical Recurrence | Open Journal of Urology | 2021 |
Perceptions of partial gland ablation for prostate cancer among men on active surveillance: A qualitative study | | |
The utility of a deep learning-based algorithm for bone scintigraphy in patient with prostate cancer | Annals of Nuclear Medicine | 2020 |
Chemotherapy and Prostate Cancer | | 2021 |
Androgen Deprivation Therapy | | 2021 |
Medical Oncology | | 2008 |
Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity. | Value in Health | 2022 |
Prostate Cancer | | 2020 |
Comparative evaluation of results of high and low dose rate brachytherapy in treatment of localized prostate cancer | Onkologiya Zhurnal Imeni P A Gertsena | 2020 |
Chemotherapeutic Agents for Urologic Oncology: Basic Principles | | 2020 |
The Value of Incorporating Multiparametric MRI for Active Surveillance in Patients with Prostate Cancer | | 2020 |
Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort | PLoS ONE | 2020 |
Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer | Frontiers in Oncology | 2020 |
Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends | Cancers | 2021 |
Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution | Brachytherapy | 2021 |
Radiotherapy for Prostate Cancer | | 2021 |
Validity of using cancer registry data for comparative effectiveness research | | |
Four years of clinical experience with Radium-223 for the treatment of castration-resistant prostate cancer | Revista Espanola De Medicina Nuclear E Imagen Molecular | 2019 |
Commercial gene expression tests for prostate cancer prognosis provide paradoxical estimates of race-specific risk | | |
Androgen Deprivation Therapy for Advanced Prostate Cancer | | 2019 |
Prostate Cancer | | 2019 |
Androgen Deprivation Therapy for Advanced Prostate Cancer | | 2019 |
SBRT for High-Risk Prostate Cancer | | 2019 |
How We Led the Japanese Low-Dose-Rate Brachytherapy to Successful Practice (Urologist Perspective) | | 2019 |
Risk Assessment Among Patients Receiving Primary ADT for Prostate Cancer | | 2018 |
[8. How We Can Treat the Patients with Prostate Cancer-Surgical Option and Change over Time] | Japanese Journal of Radiological Technology | 2018 |
Side Effects of Medical Cancer Therapy in Genitourinary Malignancies | | 2018 |
Prostate Gland Pathology | | 2018 |
Evaluation and Treatment for High-Risk Prostate Cancer | | 2018 |
ONCOLOGIC OUTCOMES OF RADICAL PROSTATECTOMY AND PROGNOSTIC STRATIFICATION IN PATIENTS WITH CLINICALLY LOCALLY ADVANCED PROSTATE CANCER | EUREKA Health Sciences | 2017 |
Komorbidität in der geriatrische Urologie | | 2016 |
Genitourinary Sites | | 2016 |
Prostate Cancer | | 2015 |
Komorbidität in der geriatrische Urologie | | 2015 |
Pelvic Lymphadenectomy for Prostate and Bladder Cancer | | 2015 |
New Imaging Modalities | Current Clinical Urology | 2014 |
[Comparison of ventral and dorsal lymph node metastases of obturator nerve in radical prostatectomy] | Japanese Journal of Urology | 2014 |
Prostate Carcinoma Surveillance Counterpoint: USA | | 2013 |
Genitourinary Cancer | | 2013 |
Decision Making in Elderly Localized Prostate Cancer | | 2013 |
Clinical Management of Elderly Patients’ Metastatic Prostate Cancer: Other Treatments and Supportive Care | | 2013 |
The Role for Radical Prostatectomy in Advanced Prostate Cancer | | 2012 |
Cancer de la prostate | | 2011 |
Prostate Cancer | | 2010 |
Prostate Cancer Stem/Progenitor Cells | | 2009 |
Can Pre-treatment Quantitative Multi-parametric MRI Predict the Outcome of Radiotherapy in Patients with Prostate Cancer? | Academic Radiology | 2021 |
Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer | Journal of Medical Radiation Sciences | 2021 |
Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer | Cancers | 2021 |
Prostate-specific antigen cutoff value for ordering sodium fluoride positron emission tomography/computed tomography bone scan in patients with prostate cancer | World Journal of Nuclear Medicine | 2018 |
Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatectomy | World Journal of Nuclear Medicine | 2017 |
Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer | Radiation Oncology Journal | 2015 |
Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using a Couple-Focused mHealth Symptom Self-Management Program: Protocol for a Feasibility Study | JMIR Research Protocols | 2018 |
Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients | PLoS ONE | 2018 |
Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO) | PLoS ONE | 2017 |
On Risk Estimation versus Risk Stratification in Early Prostate Cancer | PLoS Medicine | 2016 |
Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients | Prostate Cancer and Prostatic Diseases | 2021 |
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis | Critical Reviews in Oncology/Hematology | 2020 |
Magnetic resonance as imaging diagnostic tool in prostate cancer: New evidences-The EAU Section of Uro-Technology position | Actas Urológicas Españolas | 2020 |
Efficacy of enzalutamide and apalutamide in the treatment of non-metastasic castration-resistant prostate cancer: Indirect comparison | Actas Urológicas Españolas | 2019 |
Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer | Drugs | 2021 |
High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer | | 2019 |
Management of Localized and Locally Advanced Prostate Cancer | | 2020 |